The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.
The present invention relates to polycyclic compounds, processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
本发明涉及多环化合物,其制备过程,它们作为药物的用途以及包含它们的药物组合物。
Reverse Isoxazoles
申请人:Albert Rainer
公开号:US20090137636A1
公开(公告)日:2009-05-28
The present invention relates to polycyclic compounds, processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
本发明涉及多环化合物,其制备过程,其作为药物的用途以及包含它们的药物组合物。
3,5-di(aryl or heteroaryl)isoxazoles and 1,2,4-oxadiazoles as S1P1 receptor agonists, immunosuppresssive and anti-inflammatory agents
申请人:Novartis AG
公开号:EP2233473A1
公开(公告)日:2010-09-29
The present invention relates to polycyclic compounds, processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
X is -n= or -CH=; ring A is phenyl or pyridyl; R1 is phenyl substituted by both haloalkyl and cycloalkyl.